Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion’s product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company’s lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company’s lead preclinical program is the Neo-Kidney Augment™, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure. Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder. Tengion has worldwide rights to its product candidates.
Industry
Biotechnology
Specialties
Regenerative Medicine
Headquarters
East Norriton, PA, United States
Company size
100-200 employees
The most popular email templates:
Tengion’s email formatsPercentage
lastNameInitial.firstNameInitiald.j@tengion.com30%
firstNameInitiallastNamejdoe@tengion.com45%
lastNameInitial.firstNamed.jane@tengion.com34%
lastNameInitial_firstNameInitiald_j@tengion.com60%
lastNameInitialfirstNamedjane@tengion.com49%
firstNameInitial-lastNamej-doe@tengion.com88%

Our Integration Partners

+ 13 more